Novel Therapeutic Agents for the Treatment of Autoimmune Diseases

Provides a detailed survey of therapies for autoimmune diseases, exploring the rationale for their use and clinical data regarding their potential benefit. <p>Introduction <br><br>The Evaluation of Biological Agents, Vibeke Strand and David L. Scott<br><br>Cellular Targeted Therapies <br><br>Anti-CD5 Ricin A Chain Immunoconjugate Therapy in Rheumatoid Arthritis, John J. Cash<br>Early Clinical Studies of IL-2 Fusion Toxin in Patients with Severe Rheumatoid Arthritis <br><br>Recent-Onset Insulin-Dependent Diabetes Mellitus, and Psoriasis, Thasia G. Woodworth and Karen Parker<br>Chimeric Anti-CD4 Antibody as a Potential Therapeutic Agent for Rheumatoid Arthritis, Larry W. Moreland and William J. Koopman<br>CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis, F. C. Breedveld<br>The Use of CE9.1, a Primatized Monoclonal Anti-CD4, in the Treatment of Rheumatoid Arthritis, David E. Yocum, Alan M. Solinger, and John Lipani <br>CAMPATH-1H Therapy in Autoimmune Diseases, Richard A. Watts and John D. Isaacs<br>CAMPATH-1H in Rheumatoid Arthritis: United States Experience, David E. Yocum and Jeffrey M. Johnston <br><br>Cytokine Targeted Therapies <br><br>Interferon-Gamma in the Treatment of Rheumatoid Arthritis, Eric M. Veys, Herman Mielants, and Gust Verbruggen <br>Tumor Necrosis Factor Blockade in Rheumatoid Arthritis, Michael J. Elliott, Marc Feldmann, and Ravinder N. Maini <br>Engineered Human Anti-Tumor Necrosis Factor-Alpha (TNFaAntibody, CDP571, in Rheumatoid Arthritis, Ernest H. S. Choy and Gabriel S. Panayi <br>Clinical Experience with Recombinant Human Interleukin-1 Receptor Type I (Rhu IL-1RI) in Patients with Rheumatoid Arthritis, Richard M. Pope, Barbara Drevlow, Jennifer Capezio, Rosa Lovis, and Alan Landay <br>Treatment of Rheumatoid Arthritis with Soluble Tumor Necrosis Factor Receptor, Gary R. Margolies, William J. Koopman, and Larry W. Moreland <br><br>Adhesion Molecule Targeted Therapies <br><br>Treatment of Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule-1, Arthur F. Kavanaugh and Peter E. Lipsky<br><br>Potential Antigen-Specific Therapies <br><br>T-Cell-Receptor Peptide Therapy for Multiple Sclerosis, Arthur A. Vanderbark, Dennis N. Bourdette, Ruth H. Whitham, and Halina Offner<br>T-Cell Receptor Peptide Vaccination Studies in Rheumatoid Arthritis, Louis W. Heck, Larry W. Moreland, and William J. Koopman<br>Oral Tolerance for the Treatment of Autoimmune Disease, David A Hafler and Howard L. Weiner<br>Oral Tolerance, David E. Trentham<br>Intravenous Immunoglobulin (IVIg) in the Treatment of Autoimmune Diseases, Vibeke Strand and Martin L. Lee <br><br>Purine and Pyrimidine Synthesis Inhibitors <br><br>Inhibitors of De Novo Nucleotide Synthesis in the Treatment of Rheumatoid Arthritis, Robert I. Fox and Randall E. Morris <br>Leflunomide: A New Immunosuppressive Drug, David L. Scott and Vibeke Strand <br><br>Future Directions <br><br>An Assessment of Novel Agents in the Treatment of the Rheumatic Diseases, Vibeke Strand and Lee S. Simon</p>